Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
66 hedge funds and large institutions have $373M invested in Revance Therapeutics, Inc. in 2014 Q1 according to their latest regulatory filings, with 66 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EWM
Essex Woodlands Management
The Woodlands,
Texas
|
+$143M |
| 2 |
VAM
Visium Asset Management
New York
|
+$28.1M |
| 3 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$16.6M |
| 4 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$16.2M |
| 5 |
Millennium Management
New York
|
+$10M |
Top Sellers
RVNC Hedge Fund Activity: Q1 2014 in Review
66 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q1 2014, worth a combined $373M.
Buyers outnumbered sellers: 66 funds opened new RVNC positions and 0 closed out — a net gain of 66 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Essex Woodlands Management, opening a new position worth an estimated $143M.
- 66 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q1 2014, up from 0 in Q4 2013.
- Funds reported $373M of Revance Therapeutics, Inc. stock for Q1 2014.
- 66 funds opened new Revance Therapeutics, Inc. positions in Q1 2014 and 0 closed out, a net change of +66 holders.
- The largest Revance Therapeutics, Inc. buyer in Q1 2014 was Essex Woodlands Management, an estimated $143M added.
Based on aggregated 13F filings for Q1 2014.